TY - JOUR
T1 - Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction
T2 - Results of the Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial
AU - Morrow, David A.
AU - Antman, Elliott M.
AU - Sayah, Assaad
AU - Schuhwerk, Kristin C.
AU - Giugliano, Robert P.
AU - de Lemos, James A
AU - Waller, Michael
AU - Cohen, Sidney A.
AU - Rosenberg, Donald G.
AU - Cutler, Sally S.
AU - McCabe, Carolyn H.
AU - Walls, Ron M.
AU - Braunwald, Eugene
N1 - Funding Information:
The Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial was supported by Centocor, Inc. Rapid assays for cardiac markers were provided by Spectral Diagnostics, Frederick, MDECG and transmission equipment supported by Medtronic Physio-Control, Redmond, Washington.
PY - 2002/7/3
Y1 - 2002/7/3
N2 - OBJECTIVES: The Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial tested the feasibility of prehospital initiation of the bolus fibrinolytic reteplase (rPA) and determined the time saved by prehospital rPA in the setting of contemporary emergency cardiac care. BACKGROUND: Newer bolus fibrinolytics have undergone only limited evaluation for prehospital administration. In addition, as door-to-drug times have decreased, the relevance of findings from prior trials of prehospital fibrinolysis has become less certain. METHODS: Patients (n = 315) with ST-elevation myocardial infarction (STEMI) were enrolled in 20 emergency medical systems in North America. The time from emergency medical service (EMS) arrival to administration of a fibrinolytic was compared between study patients receiving prehospital rPA and sequential control patients from 6 to 12 months before the study who received a fibrinolytic in the hospital. RESULTS: Acute myocardial infarction was confirmed in 98%. The median time from EMS arrival to initiation of rPA was 31 min (25th to 75th percentile, 24 min to 37 min). The time from EMS arrival to in-hospital fibrinolytic for 630 control patients was 63 min (25th to 75th percentile, 48 min to 89 min), resulting in a time saved of 32 min (p < 0.0001). By 30 min after first medical contact, 49% of study patients had received the first bolus of fibrinolytic compared with only 5% of controls (p < 0.0001). In-hospital mortality was 4.7%. Intracranial hemorrhage occurred in 1.0%. CONCLUSIONS: Prehospital administration of rPA is a feasible approach to accelerating reperfusion in patients with STEMI. Valuable time savings can be achieved in the setting of contemporary transport and door-to-drug times and may translate into an improvement in clinical outcomes.
AB - OBJECTIVES: The Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial tested the feasibility of prehospital initiation of the bolus fibrinolytic reteplase (rPA) and determined the time saved by prehospital rPA in the setting of contemporary emergency cardiac care. BACKGROUND: Newer bolus fibrinolytics have undergone only limited evaluation for prehospital administration. In addition, as door-to-drug times have decreased, the relevance of findings from prior trials of prehospital fibrinolysis has become less certain. METHODS: Patients (n = 315) with ST-elevation myocardial infarction (STEMI) were enrolled in 20 emergency medical systems in North America. The time from emergency medical service (EMS) arrival to administration of a fibrinolytic was compared between study patients receiving prehospital rPA and sequential control patients from 6 to 12 months before the study who received a fibrinolytic in the hospital. RESULTS: Acute myocardial infarction was confirmed in 98%. The median time from EMS arrival to initiation of rPA was 31 min (25th to 75th percentile, 24 min to 37 min). The time from EMS arrival to in-hospital fibrinolytic for 630 control patients was 63 min (25th to 75th percentile, 48 min to 89 min), resulting in a time saved of 32 min (p < 0.0001). By 30 min after first medical contact, 49% of study patients had received the first bolus of fibrinolytic compared with only 5% of controls (p < 0.0001). In-hospital mortality was 4.7%. Intracranial hemorrhage occurred in 1.0%. CONCLUSIONS: Prehospital administration of rPA is a feasible approach to accelerating reperfusion in patients with STEMI. Valuable time savings can be achieved in the setting of contemporary transport and door-to-drug times and may translate into an improvement in clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=0037014565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037014565&partnerID=8YFLogxK
U2 - 10.1016/S0735-1097(02)01936-8
DO - 10.1016/S0735-1097(02)01936-8
M3 - Article
C2 - 12103258
AN - SCOPUS:0037014565
SN - 0735-1097
VL - 40
SP - 71
EP - 77
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 1
ER -